Bloodstream Infection of Carbapenem-Resistant Proteus Mirabilis

NCT06542965 | Completed

• 1 other identifier: DEU-INF-IRMAK-1
• Study Type: observational
• Target: 67
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to determine the clinical characteristics, risk factors, and resistance mechanisms of patients with carbapenem-resistant P. mirabilis bacteremia.Patients with P. mirabilis growth in blood culture samples sent to bacteriology laboratory between 2018 and 2021 were retrospectively analyzed. Patients meeting the inclusion criteria were divided into carbapenem-resistant and carbapenem- susceptible groups. The investigators recorded demographic data, clinical features, and laboratory findings. Resistance genes were investigated in carbapenem-resistant isolates using PCR.

Conditions

Proteus Mirabilis Infection; Bacteremia; Carbapenem Resistant Bacterial Infection

Keywords

Proteus mirabilis; bacteremia; carbapenem resistance; resistance mechanisms; PCR

Outcome Measures

Primary Outcomes (5)

• Carbapenem Use

  number of patients using carbapenem before P. mirabilis growth in blood cultures

  1 year

• Intensive Care Units

  number of patients admission in ıntensive care units before P. mirabilis growth in blood cultures

  1 year

• Mortality

  number of patients who died

  30 days

• Length of hospital stay

  Length of hospital stay days

  1 year

• Presence of chronic disease

  number of patients with chronic disease

  1 year

Study Arms (2)

Case (Patients with carbapenem-resistant P. mirabilis)

Patients with carbapenem-resistant P. mirabilis (CRPM) growth in blood culture were included in the case group

Other: Non-Interventional Research

Control (Patients with carbapenem- susceptible P. mirabilis)

Patients with carbapenem- susceptible P. mirabilis (CSPM) growth in blood culture were included in the control group

Other: Non-Interventional Research

Interventions

Non-Interventional Research OTHER

Non-Interventional Research

Case (Patients with carbapenem-resistant P. mirabilis); Control (Patients with carbapenem- susceptible P. mirabilis)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

. Inpatients aged 18 years and older with P. mirabilis growth in blood cultures were included in the study, while samples taken in emergency departments, outpatient clinics, day treatment units and recurrent growths of the same patient were excluded.

You may qualify if:

• Inpatients aged 18 years and older
• P. mirabilis growth in blood cultures

You may not qualify if:

• Samples taken in emergency departments, outpatient clinics, day treatment units
• Recurrent growths of the same patient

Sponsors & Collaborators

• Dokuz Eylul University: lead

Study Sites (1)

Dokuz Eylül University

Izmir, 35400, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITH DNA

blood culture samples

MeSH Terms

Conditions

Bacteremia

Condition Hierarchy (Ancestors)

Bacterial Infections; Bacterial Infections and Mycoses; Infections; Sepsis; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Çağlar IRMAK

  Dokuz Eylul University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Month
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator, Medical Specialists in Infectious Diseases

Study Record Dates

• First Submitted: July 31, 2024
• First Posted: August 7, 2024
• Study Start: January 1, 2018
• Primary Completion: December 31, 2021
• Study Completion: January 1, 2023
• Last Updated: August 7, 2024

Record last verified: 2024-08

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)